---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-247004"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:13:29.706109+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports positive Phase 2b CARPO data: 100% reduction in severe respiratory failure with high-dose Auxora

## Summary
- 100% relative risk reduction (p=0.0027) in new-onset severe respiratory failure for combined high/medium dose vs low dose/placebo.
- Stratified win ratio of 1.640 (p=0.0372) for high dose (2.0 mg/kg) Auxora vs placebo across key endpoints.
- No drug-related serious adverse events or deaths at high dose; trend of decreasing TESAE rates with higher dose.
- Planning end-of-Phase 2 meeting with FDA to design Phase 3 trial of Auxora in acute pancreatitis with SIRS.
- Median time to medically indicated discharge reduced by 15 hours for high dose vs placebo (89 vs 104 hours).

## SEC filing metadata
- accession: 0001193125-24-247004
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312524247004/0001193125-24-247004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312524247004/d885957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-247004
- JSON: https://secwatch.observer/filing/0001193125-24-247004.json
- Plain text: https://secwatch.observer/filing/0001193125-24-247004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.